Get the Stockscreener App
5.26
1.15%
0.06
After Hours:
5.27
0.010
+0.19%
Journey Medical Corp stock is traded at $5.26, with a volume of 120.39K.
It is up +1.15% in the last 24 hours and down -27.15% over the past month.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
See More
Previous Close:
$5.20
Open:
$5.23
24h Volume:
120.39K
Relative Volume:
0.62
Market Cap:
$143.76M
Revenue:
$61.86M
Net Income/Loss:
$-11.43M
P/E Ratio:
-10.92
EPS:
-0.4818
Net Cash Flow:
$-12.52M
1W Performance:
+6.26%
1M Performance:
-27.15%
6M Performance:
-26.94%
1Y Performance:
-15.30%
1-Day Range:
$5.20
$5.41
1-Week Range:
$4.985
$5.41
52-Week Range:
$4.31
$9.555
Journey Medical Corp Stock (DERM) Company Profile
Name
Journey Medical Corp
Sector
Phone
480-434-6670
Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
5.26 | 141.30M | 61.86M | -11.43M | -12.52M | -0.4818 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | H.C. Wainwright | Buy |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | ROTH MKM | Buy |
| Dec-07-21 | Initiated | B. Riley Securities | Buy |
Journey Medical Corp Stock (DERM) Latest News
Stock List: Research Stocks from Around the World - GuruFocus
DERM Technical Analysis & Stock Price Forecast - Intellectia AI
Journey Medical Corp stock: What investors need to know amid volatility - AD HOC NEWS
Wasatch Advisors holds 2.13M Journey Medical (NASDAQ: DERM) — 10% stake - Stock Titan
DERM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of “Hold” by Analysts - Defense World
Journey Medical Corporation (NASDAQ:DERM) Given Consensus Rating of "Hold" by Analysts - MarketBeat
US Stocks Recap: Can Journey Medical Corporation be the next market leaderPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Short Squeeze: Can Journey Medical Corporation reach all time highs this year2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why The Journey Medical (DERM) Narrative Is Shifting With New Targets And Going Concern Risks - Yahoo Finance
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Update: Can Journey Medical Corporation reach all time highs this yearWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Journey Medical (NASDAQ:DERM) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Journey Medical Corporation (NASDAQ:DERM) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Forecasts Journey Medical Q1 Earnings - MarketBeat
Market Pulse: What hedge funds are buying Journey Medical CorporationQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Journey Medical Corp (DERM) - The Globe and Mail
Journey Medical (DERM) Q4 Results: Examining Essential Metrics Compared to Projections - Bitget
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Journey Medical Corporation 2025 Annual Report: Dermatology Product Portfolio, FDA Approvals, Market Strategy, and Intellectual Property Overview - Minichart
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Journey Medical Corporation Q4 2025 Earnings Call Summary - finance.yahoo.com
HC Wainwright Reaffirms Buy Rating for Journey Medical (NASDAQ:DERM) - marketbeat.com
Journey Medical stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Journey Medical 2025 10-K: $61.9M Revenue, $(11.4)M Net Loss - TradingView
Journey Medical earnings missed by $0.50, revenue fell short of estimates - Investing.com South Africa
Journey Medical Corp (DERM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
DERM Drops 25%: The Contradiction of a Positive Analyst Rating During Sharp Intraday Decline - Bitget
Earnings call transcript: Journey Medical reports Q4 2025 growth, EMROSI sales boost - uk.investing.com
Journey Medical Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Journey Medical reports Q4 2025 growth, EMROSI sales boost By Investing.com - Investing.com South Africa
Journey Medical Corp reports results for the quarter ended September 30Earnings Summary - TradingView
Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Journey Medical (Nasdaq: DERM) adds Emrosi rosacea drug and global deals - Stock Titan
Journey posts FY2025 revenue $61.9M, narrowed net loss to $11.4M and reports $2.9M Adjusted EBITDA - TradingView
Journey Medical (NASDAQ: DERM) grows 2025 revenue to $61.9M as losses narrow - stocktitan.net
New rosacea drug drove $14.7M for Journey Medical after April launch - Stock Titan
Rate Cut: Is Journey Medical Corporation undervalued by DCF analysis2026 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Earnings Scheduled For March 25, 2026 - Benzinga
Journey Medical Corp stock faces key test ahead of Q4 2025 earnings release on March 25, 2026 - AD HOC NEWS
Journey Medical Corp (DERM) Q4 2025: Everything You Need To Know Ahead Of Earnings - gurufocus.com
Journey Medical Corp expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Pullback Watch: Is Journey Medical Corporation undervalued by DCF analysisWeekly Investment Recap & Capital Protection Trading Alerts - baoquankhu1.vn
Danone Sets New Sustainability Targets with Second Phase of Impact Journey - Food & Beverage Outlook
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - The Manila Times
WallabyPhenox Restructures Debt and Accelerates Global Growth - The Manila Times
Off The Hook Yachts Expands Mid-Atlantic Presence with Strategic Waterfront Hub to Increase Inventory Velocity and Margin Capture - The Manila Times
Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available - The Manila Times
GSI Technology Concludes Strategic Alternatives Review - The Manila Times
Dermatology drug seller Journey Medical to detail 2025 results on Mar. 25 - Stock Titan
Journey Medical Corp Stock (DERM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):